NTRA
Natera, Inc. NASDAQ Listed Jul 1, 2015$231.41
+2.19%
vs $226.44
Mkt Cap $33.1B
52w Low $131.81
80.0% of range
52w High $256.36
50d MA $207.88
200d MA $206.57
P/E (TTM)
-152.2x
EV/EBITDA
—
P/B
18.5x
Debt/Equity
0.1x
ROE
-12.2%
P/FCF
290.0x
RSI (14)
55.30
ATR (14)
$10.12
Beta
1.68
50d MA
$207.88
200d MA
$206.57
Avg Volume
1.6M
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.
13011 McCallen Pass Building A · Austin, CA 78753 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 7, 2026 | AMC | -0.53 | -0.56 | -5.7% | 219.82 | -4.5% | -11.6% | +2.5% | +2.5% | -4.4% | +0.8% | — |
| Feb 26, 2026 | AMC | -0.51 | 0.35 | +168.4% | 216.10 | -2.4% | -3.7% | -3.8% | +3.4% | -1.9% | -2.9% | — |
| Nov 6, 2025 | AMC | -0.39 | -0.64 | -65.9% | 198.48 | -6.1% | +0.5% | +3.5% | +0.0% | +1.3% | -4.2% | — |
| Aug 7, 2025 | AMC | -0.62 | -0.74 | -20.2% | 141.08 | +14.8% | +7.7% | +3.3% | +1.8% | -1.3% | +0.5% | — |
| May 8, 2025 | AMC | -0.64 | -0.50 | +21.9% | 162.57 | +1.3% | -6.5% | +3.5% | -3.2% | -0.6% | -1.3% | — |
| Feb 27, 2025 | AMC | -0.38 | -0.41 | -7.6% | 156.61 | +2.1% | -0.7% | -8.0% | -0.5% | +3.9% | -4.3% | — |
| Nov 12, 2024 | AMC | -0.57 | -0.26 | +54.4% | 135.12 | +15.1% | +19.1% | -6.1% | -3.3% | +5.0% | +5.7% | — |
| Aug 8, 2024 | AMC | -0.69 | -0.30 | +56.5% | 107.70 | -2.0% | +6.4% | +0.6% | +3.3% | -0.4% | +3.2% | — |
| May 9, 2024 | AMC | -0.71 | -0.56 | +21.1% | 95.55 | +13.1% | +10.2% | -1.9% | +2.1% | +1.7% | +1.1% | — |
| Feb 28, 2024 | AMC | -0.73 | -0.64 | +12.3% | 76.55 | +12.0% | +13.0% | +3.4% | +0.9% | -2.9% | +3.0% | — |
| Nov 8, 2023 | AMC | -0.96 | -0.95 | +1.0% | 41.34 | +14.9% | +9.8% | +3.0% | +3.9% | +7.4% | +1.6% | — |
| Aug 3, 2023 | AMC | -1.09 | -0.97 | +11.0% | 43.40 | +14.0% | +17.6% | +0.0% | +3.3% | -0.9% | +2.1% | — |
| May 9, 2023 | AMC | -1.15 | -1.23 | -7.0% | 53.00 | +2.6% | -3.4% | +0.8% | -1.0% | +2.1% | -2.2% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 12 | RBC Capital Mkts | Reiterates | Outperform | $275 | $219.23 | $223.71 | +2.0% | -3.3% | +2.3% | +1.4% | +2.9% | +2.2% |
| Jun 2 | Wolfe Research | Reiterates | Outperform | $260 | $218.81 | $214.80 | -1.8% | -2.8% | -0.4% | +4.8% | -3.1% | -0.9% |
| Mar 3 | Morgan Stanley | Maintains | Overweight → Overweight | — | $200.17 | $195.67 | -2.2% | +3.4% | -1.9% | -2.9% | +0.5% | +3.6% |
| Feb 27 | Evercore ISI | Maintains | Outperform → Outperform | — | $216.10 | $211.02 | -2.4% | -3.7% | -3.8% | +3.4% | -1.9% | -2.9% |
| Feb 27 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $216.10 | $211.02 | -2.4% | -3.7% | -3.8% | +3.4% | -1.9% | -2.9% |
| Feb 27 | Baird | Maintains | Outperform → Outperform | — | $216.10 | $211.02 | -2.4% | -3.7% | -3.8% | +3.4% | -1.9% | -2.9% |
| Jan 5 | Guggenheim | Maintains | Buy → Buy | — | $228.84 | $229.88 | +0.5% | +3.7% | +4.8% | +2.3% | -5.8% | -2.2% |
| Dec 22 | Canaccord Genuity | Maintains | Buy → Buy | — | $231.96 | $233.91 | +0.8% | +1.6% | -0.1% | +0.1% | -0.8% | -1.0% |
| Dec 15 | JP Morgan | Maintains | Overweight → Overweight | — | $231.95 | $229.29 | -1.1% | -1.5% | -0.4% | -0.8% | -0.3% | +3.2% |
| Dec 15 | Barclays | Maintains | Overweight → Overweight | — | $231.95 | $229.29 | -1.1% | -1.5% | -0.4% | -0.8% | -0.3% | +3.2% |
| Dec 15 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $231.95 | $229.29 | -1.1% | -1.5% | -0.4% | -0.8% | -0.3% | +3.2% |
| Dec 8 | Canaccord Genuity | Maintains | Buy → Buy | — | $244.55 | $245.33 | +0.3% | -2.2% | -1.5% | -1.0% | -0.9% | +0.4% |
| Dec 5 | BTIG | Maintains | Buy → Buy | — | $242.06 | $242.22 | +0.1% | +1.0% | -2.2% | -1.5% | -1.0% | -0.9% |
| Dec 2 | Morgan Stanley | Maintains | Overweight → Overweight | — | $234.25 | $236.95 | +1.2% | +1.0% | +0.7% | +1.6% | +1.0% | -2.2% |
| Nov 25 | JP Morgan | Maintains | Overweight → Overweight | — | $238.58 | $240.40 | +0.8% | -0.9% | +0.3% | +0.7% | -1.9% | +1.0% |
| Nov 18 | UBS | Maintains | Buy → Buy | — | $206.04 | $204.73 | -0.6% | +3.7% | +2.2% | +3.3% | +2.3% | +3.4% |
| Nov 13 | Stephens & Co. | Maintains | Overweight → Overweight | — | $209.50 | $206.46 | -1.5% | -4.2% | +1.8% | +0.9% | +3.7% | +2.2% |
| Nov 11 | Morgan Stanley | Maintains | Overweight → Overweight | — | $206.63 | $207.44 | +0.4% | +0.0% | +1.3% | -4.2% | +1.8% | +0.9% |
| Nov 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $206.63 | $207.44 | +0.4% | +0.0% | +1.3% | -4.2% | +1.8% | +0.9% |
| Nov 7 | BTIG | Maintains | Buy → Buy | — | $198.48 | $186.28 | -6.1% | +0.5% | +3.5% | +0.0% | +1.3% | -4.2% |
| Nov 7 | Evercore ISI | Maintains | Outperform → Outperform | — | $198.48 | $186.28 | -6.1% | +0.5% | +3.5% | +0.0% | +1.3% | -4.2% |
| Nov 7 | Barclays | Maintains | Overweight → Overweight | — | $198.48 | $186.28 | -6.1% | +0.5% | +3.5% | +0.0% | +1.3% | -4.2% |
| Nov 7 | Canaccord Genuity | Maintains | Buy → Buy | — | $198.48 | $186.28 | -6.1% | +0.5% | +3.5% | +0.0% | +1.3% | -4.2% |
| Nov 7 | JP Morgan | Maintains | Overweight → Overweight | — | $198.48 | $186.28 | -6.1% | +0.5% | +3.5% | +0.0% | +1.3% | -4.2% |
| Nov 7 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $198.48 | $186.28 | -6.1% | +0.5% | +3.5% | +0.0% | +1.3% | -4.2% |
| Oct 23 | BTIG | Maintains | Buy → Buy | — | $188.02 | $187.16 | -0.5% | +3.7% | -1.3% | -0.2% | -1.4% | +1.7% |
| Oct 14 | Canaccord Genuity | Maintains | Buy → Buy | — | $174.17 | $173.00 | -0.7% | -0.8% | +3.8% | +0.6% | +0.6% | +3.8% |
| Aug 15 | Stephens & Co. | Maintains | Overweight → Overweight | — | $158.44 | $158.46 | +0.0% | +2.9% | -1.1% | -0.6% | +0.3% | +0.8% |
| Aug 11 | Piper Sandler | Maintains | Overweight → Overweight | — | $151.95 | $151.05 | -0.6% | +3.3% | +1.8% | -1.3% | +0.5% | +2.9% |
| Aug 8 | RBC Capital | Maintains | Outperform → Outperform | — | $141.08 | $162.00 | +14.8% | +7.7% | +3.3% | +1.8% | -1.3% | +0.5% |
| Aug 8 | Barclays | Maintains | Overweight → Overweight | — | $141.08 | $162.00 | +14.8% | +7.7% | +3.3% | +1.8% | -1.3% | +0.5% |
| May 15 | Piper Sandler | Maintains | Overweight → Overweight | — | $151.34 | $151.34 | +0.0% | -1.3% | +2.1% | +0.4% | +0.8% | -2.2% |
| May 9 | UBS | Maintains | Buy → Buy | — | $162.57 | $164.75 | +1.3% | -6.5% | +3.5% | -3.2% | -0.6% | -1.3% |
| May 9 | Barclays | Maintains | Overweight → Overweight | — | $162.57 | $164.75 | +1.3% | -6.5% | +3.5% | -3.2% | -0.6% | -1.3% |
| Apr 10 | Barclays | Maintains | Overweight → Overweight | — | $151.97 | $146.24 | -3.8% | -5.7% | +3.3% | +0.3% | +2.2% | -1.0% |
| Mar 5 | Morgan Stanley | Maintains | Overweight → Overweight | — | $142.35 | $142.09 | -0.2% | +3.9% | -4.3% | -0.6% | -5.7% | +5.6% |
| Mar 4 | Piper Sandler | Maintains | Overweight → Overweight | — | $143.11 | $140.37 | -1.9% | -0.5% | +3.9% | -4.3% | -0.6% | -5.7% |
| Feb 28 | Baird | Maintains | Outperform → Outperform | — | $156.61 | $159.94 | +2.1% | -0.7% | -8.0% | -0.5% | +3.9% | -4.3% |
| Feb 28 | Canaccord Genuity | Maintains | Buy → Buy | — | $156.61 | $159.94 | +2.1% | -0.7% | -8.0% | -0.5% | +3.9% | -4.3% |
| Feb 26 | Canaccord Genuity | Maintains | Buy → Buy | — | $156.00 | $155.31 | -0.4% | +2.9% | -2.5% | -0.7% | -8.0% | -0.5% |
| Jan 28 | Goldman Sachs | Maintains | Buy → Buy | — | $165.26 | $165.49 | +0.1% | +1.7% | +0.1% | +4.8% | +0.4% | -0.2% |
| Jan 17 | Guggenheim | Maintains | Buy → Buy | — | $168.50 | $168.92 | +0.2% | -6.0% | +5.7% | +2.7% | -0.1% | -2.5% |
| Jan 10 | Bernstein | Maintains | Outperform → Outperform | — | $176.61 | $173.02 | -2.0% | -0.9% | -3.3% | -2.1% | +2.8% | -1.1% |
| Jan 3 | Canaccord Genuity | Maintains | Buy → Buy | — | $160.60 | $162.65 | +1.3% | +4.4% | +2.8% | -1.1% | +3.6% | -0.9% |
| Dec 13 | JP Morgan | Maintains | Overweight → Overweight | — | $166.45 | $168.20 | +1.1% | +0.1% | +2.6% | -1.5% | -7.7% | +1.9% |
| Nov 18 | Piper Sandler | Maintains | Overweight → Overweight | — | $146.06 | $150.60 | +3.1% | +5.0% | +5.7% | +3.6% | +0.9% | -1.2% |
| Nov 14 | Morgan Stanley | Maintains | Overweight → Overweight | — | $160.97 | $160.79 | -0.1% | -6.1% | -3.3% | +5.0% | +5.7% | +3.6% |
| Nov 13 | Canaccord Genuity | Maintains | Buy → Buy | — | $135.12 | $155.56 | +15.1% | +19.1% | -6.1% | -3.3% | +5.0% | +5.7% |
| Nov 13 | TD Cowen | Maintains | Buy → Buy | — | $135.12 | $155.56 | +15.1% | +19.1% | -6.1% | -3.3% | +5.0% | +5.7% |
| Nov 13 | Baird | Maintains | Outperform → Outperform | — | $135.12 | $155.56 | +15.1% | +19.1% | -6.1% | -3.3% | +5.0% | +5.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | Chapman Rowan E | — | Sell | 2,964 | $216.78 | $643K | 3,124 | +2.19% | — |
| Jun 15, 2026 | Sheena Jonathan | — | Sell | 300 | $213.54 | $64K | 249,352 | +2.19% | — |
| Jun 15, 2026 | Sheena Jonathan | — | Sell | 500 | $212.42 | $106K | 249,652 | +2.19% | — |
| Jun 15, 2026 | Sheena Jonathan | — | Sell | 600 | $211.34 | $127K | 250,152 | +2.19% | — |
| Jun 15, 2026 | Sheena Jonathan | — | Sell | 1,750 | $210.29 | $368K | 250,752 | +2.19% | — |
| Jun 15, 2026 | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | Sell | 400 | $218.72 | $87K | 2,277,843 | +2.88% | — |
| Jun 15, 2026 | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | Sell | 3,811 | $217.60 | $829K | 2,278,243 | +2.88% | — |
| Jun 15, 2026 | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | Sell | 6,741 | $216.81 | $1.5M | 2,282,054 | +2.88% | — |
| Jun 15, 2026 | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | Sell | 11,877 | $215.91 | $2.6M | 2,288,795 | +2.88% | — |
| Jun 15, 2026 | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | Sell | 10,338 | $214.72 | $2.2M | 2,300,672 | +2.88% | — |
| Jun 15, 2026 | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | Sell | 7,836 | $213.88 | $1.7M | 2,311,010 | +2.88% | — |
| Jun 15, 2026 | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | Sell | 5,097 | $212.84 | $1.1M | 2,318,846 | +2.88% | — |
| Jun 15, 2026 | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | Sell | 1,237 | $211.81 | $262K | 2,323,943 | +2.88% | — |
| Jun 15, 2026 | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | Sell | 1,832 | $210.73 | $386K | 2,325,180 | +2.88% | — |
| Jun 15, 2026 | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | Sell | 831 | $209.83 | $174K | 2,327,012 | +2.88% | — |
| Jun 12, 2026 | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | Sell | 1,605 | $219.36 | $352K | 2,327,843 | +2.88% | — |
| Jun 12, 2026 | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | Sell | 2,133 | $218.17 | $465K | 2,329,448 | +2.88% | — |
| Jun 12, 2026 | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | Sell | 4,276 | $217.32 | $929K | 2,331,581 | +2.88% | — |
| Jun 12, 2026 | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | Sell | 7,182 | $216.51 | $1.6M | 2,335,857 | +2.88% | — |
| Jun 12, 2026 | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | Sell | 3,161 | $215.38 | $681K | 2,343,039 | +2.88% | — |
| Jun 12, 2026 | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | Sell | 5,707 | $214.35 | $1.2M | 2,346,200 | +2.88% | — |
| Jun 12, 2026 | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | Sell | 5,034 | $213.43 | $1.1M | 2,351,907 | +2.88% | — |
| Jun 12, 2026 | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | Sell | 12,142 | $212.27 | $2.6M | 2,356,941 | +2.88% | — |
| Jun 12, 2026 | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | Sell | 2,957 | $211.61 | $626K | 2,369,083 | +2.88% | — |
| Jun 12, 2026 | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | Sell | 3,267 | $210.30 | $687K | 2,372,040 | +2.88% | — |
| Jun 12, 2026 | Rabinowitz Matthew | EXECUTIVE CHAIRMAN | Sell | 2,536 | $209.50 | $531K | 2,375,307 | +2.88% | — |
| Jun 5, 2026 | Marcus Gail Boxer | — | Sell | 116 | $218.81 | $25K | 6,183 | -2.84% | +1.45% |
| Jun 5, 2026 | Marcus Gail Boxer | — | Sell | 3,174 | $218.11 | $692K | 6,299 | -2.84% | +1.45% |
| Jun 5, 2026 | Marcus Gail Boxer | — | Sell | 4,694 | $217.30 | $1.0M | 9,473 | -2.84% | +1.45% |
| Jun 5, 2026 | Marcus Gail Boxer | — | Sell | 3,016 | $216.06 | $652K | 14,167 | -2.84% | +1.45% |
8-K · 5.02
!!! Very High
Natera, Inc. -- 8-K 5.02: Executive Change
Jun 16
8-K · 5.02
!!! Very High
Unknown — 8-K 5.02: Executive Change
Natera's executive compensation structure includes multi-year equity vesting incentives through 2029, indicating management retention strategy but diluting shareholder value over time through substantial stock awards.
Apr 1
8-K
Natera, Inc. -- 8-K Filing
Natera reported fourth quarter and full year 2025 financial results, with CFO Michael Brophy executing the filing on February 26, 2026.
Feb 26
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Jpmorgan Chase & Co | 13,386,667 | $2.5B | Added | Mar 2026 |
| 2 | Vanguard Capital Management Llc | 6,008,496 | $1.2B | New | Mar 2026 |
| 3 | Vanguard Portfolio Management Llc | 5,644,695 | $1.1B | New | Mar 2026 |
| 4 | Farallon Capital Management Llc | 3,207,366 | $641M | New | Mar 2026 |
| 5 | Duquesne Family Office | 3,063,606 | $613M | Added | Mar 2026 |
| 6 | Morgan Stanley | 2,468,308 | $565M | Reduced | Dec 2025 |
| 7 | Fmr Llc | 2,554,254 | $511M | Added | Mar 2026 |
| 8 | Coatue Management | 2,541,842 | $508M | Reduced | Mar 2026 |
| 9 | Franklin Resources Inc | 2,485,325 | $497M | Reduced | Mar 2026 |
| 10 | Aqr Capital Management Llc | 2,273,991 | $443M | Reduced | Mar 2026 |
| 11 | Capital World Investors | 1,467,975 | $294M | Added | Mar 2026 |
| 12 | Invesco Ltd. | 1,258,377 | $252M | Reduced | Mar 2026 |
| 13 | Rtw Investments, Lp | 1,250,000 | $250M | Reduced | Mar 2026 |
| 14 | Arrowstreet Capital, Limited Partnership | 1,191,732 | $238M | Added | Mar 2026 |
| 15 | Maverick Capital Ltd | 1,171,633 | $234M | Added | Mar 2026 |
| 16 | Lord, Abbett & Co. Llc | 1,111,505 | $222M | Reduced | Mar 2026 |
| 17 | Clearbridge Investments, Llc | 893,322 | $179M | Added | Mar 2026 |
| 18 | Northern Trust Corp | 788,445 | $158M | Added | Mar 2026 |
| 19 | Bank Of America Corp /de/ | 733,669 | $147M | Reduced | Mar 2026 |
| 20 | Ark Investment Management Llc | 684,255 | $137M | Reduced | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$33.14B
Enterprise Value
$30.56B
P/E (TTM)
-152.24x
Forward P/E
—
PEG Ratio
230.22x
P/B
18.48x
P/S
13.72x
P/FCF
289.96x
EV/EBITDA
—
Shares Out
136.7M
Financials (TTM)
Revenue
$2.31B
Net Income
-$208.2M
EBITDA
-$264.0M
Free Cash Flow
$109.1M
Op Cash Flow
$215.3M
EPS Basic
$-1.52
EPS Diluted
$-1.52
EPS Forward
$-1.78
Gross Margin
64.8%
Op Margin
-13.4%
Net Margin
-9.0%
Balance Sheet
Total Assets
$2.51B
Total Liab.
$795.6M
Total Equity
$1.71B
Cash
$1.08B
LT Debt
$0
Book Value/Sh
$12.52
Debt/Equity
0.13x
Current Ratio
3.39
Quick Ratio
3.24
Returns & Growth
ROE
-12.2%
ROA
-8.7%
ROIC
-11.1%
Rev Growth YoY
+35.9%
EPS Growth YoY
+0.7%
Price Returns
2W
+13.4%
1M
+8.3%
3M
+7.4%
6M
-6.5%
12M
+41.6%
Technicals
52W High
$256.36
52W Low
$131.81
50d MA
$207.88
200d MA
$206.57
RSI (14)
55.30
ATR (14)
$10.12
Beta
1.68
Avg Volume
1.6M
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$262.50
High
$285.00
Low
$205.00
Median
$270.00
Data updated apr 26, 2026 4:01pm
· Source: financialmodelingprep.com